Amgen Looks To U.S. Contracting Strategies To Head Off European Biosimilars
Executive Summary
Amgen is bringing U.S. contracting strategies to Europe as part of its efforts to stave off competition from biosimilars, Exec VP-Commercial Operations George Morrow said during the firm's recent annual business review
You may also be interested in...
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off
After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk